Key result
VascAgeNet aims to harmonize vascular ageing research and accelerate translation into clinical cardiovascular practice.
Why the study?
A strong collaboration between science and industry is necessary to foster innovations and breakthroughs in vascular ageing to improve clinical practice and reduce cardiovascular disease burden globally.
Supports network-driven harmonization of vascular ageing metrics; leaves open translation to routine clinical workflows or reduced CVD burden.
VascAgeNet is a new European network which will join forces in order to refine, harmonize and promote the vascular ageing concept. It aims to bring innovations in cardiovascular research from bench to bedside and to establish assessment of vascular ageing in clinical practice. The interdisciplinary, inter-country and intersectional approach will enable all important players at the different stages of the innovation process to come together, as recommended in the triple or quadruple helix model of innovation, in order to guarantee best solutions. This is deemed necessary in order for economic and revolutionary solutions to be fit for wide-spread clinical use, especially in low-income and inclusiveness target countries. Thus, a clear case exists for a strong collaboration between science and industry, to foster innovations and breakthroughs in vascular ageing in order to improve clinical practice and to reduce the burden of cardiovascular diseases globally.
No takes yet. Share an insight, caveat, or question.
Mayer et al. (2020) conducted a review in Vascular ageing. VascAgeNet was evaluated. VascAgeNet is a European network designed to refine, harmonize, and promote vascular ageing concepts by fostering collaboration between science and industry to translate cardiovascular research into clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: